METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Clinical trials for METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Custom-Made vaccine targets tough cancers in early trial
⭐️ VACCINE ⭐️ Recruiting nowThis early-phase study is testing a personalized vaccine made from each patient's unique tumor mutations. The goal is to see if it is safe and can help the immune system fight advanced breast cancer, melanoma, and non-small cell lung cancer. About 25 adults whose cancers have spr…
Matched conditions: METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated May 11, 2026 20:52 UTC
-
New vaccine combo aims to control advanced breast cancer
Disease control Recruiting nowThis study tests a vaccine called STEMVAC alongside standard hormone therapy or chemotherapy for people with hormone receptor-positive, HER2-negative breast cancer that has spread. The vaccine is designed to train the immune system to attack cancer cells. The trial will check saf…
Matched conditions: METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug duo targets hard-to-treat HER2 cancers in early trial
Disease control Recruiting nowThis early-phase trial tests the safety and best dose of two drugs given together for people with advanced breast cancer or other solid tumors that have a protein called HER2. The drugs are pidnarulex (which stops cancer cells from repairing themselves) and trastuzumab deruxtecan…
Matched conditions: METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Can a PET scan predict breast cancer drug success?
Knowledge-focused Recruiting nowThis study tests whether a special PET scan can predict if a drug combination (abemaciclib plus hormone therapy) will work for people with advanced hormone receptor-positive, HER2-negative breast cancer. About 60 participants will get the treatment and have imaging scans to see i…
Matched conditions: METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 17, 2026 02:19 UTC